Necroptosis Inhibitors for the Treatment of Inflammatory Diseases of the Gastrointestinal Tract

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of inhibitors targeting the receptor-interacting protein-1 and -3 complex (RIP1/RIP3) to treat inflammatory diseases of the gastrointestinal tract, specifically focusing on inhibiting necroptosis in epithelial cells. By blocking the pathway that leads to a form of programmed cell death (necroptosis), these inhibitors aim to reduce inflammation and disease progression in conditions such as Crohn's disease and ulcerative colitis. The invention covers a variety of inhibitor types, including small molecules (e.g., necrostatin-1), antibodies, and nucleic acids, and envisions administration alone or in combination with other therapies commonly used in treating inflammatory bowel disease.

Use CasesContent extracted from patent full text and abstract with AI.

• Treating patients with Crohn's disease by reducing intestinal inflammation and cell death.
• Managing ulcerative colitis through targeted inhibition of epithelial cell necroptosis.
• Controlling other acute or chronic inflammatory diseases of the gastrointestinal tract, such as coeliac disease, infectious colitis, or necrotizing enterocolitis.
• Combining RIP1/RIP3 inhibitors with existing therapies like anti-TNF agents, antibiotics, corticosteroids, or immunosuppressants to improve patient outcomes.
• Potentially using these inhibitors to protect intestinal epithelial integrity during chemotherapy, radiotherapy, or other therapies causing GI inflammation.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a targeted treatment approach that addresses a specific underlying pathological process (necroptosis), not just symptoms.
• May reduce or prevent the loss of key intestinal cells (Paneth and goblet cells), thus preserving gut barrier and immune function.
• Could lessen dependency on broad immunosuppressive drugs with severe side effects.
• May improve treatment efficacy, especially in patients unresponsive to current drugs like anti-TNF therapies.
• Potentially decreases the frequency of disease flare-ups, surgical interventions, and overall disease burden in chronic inflammatory bowel disease patients.
• Supports maintaining better intestinal homeostasis and reduces the risk of complications such as infections or colorectal cancer in IBD patients.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to necroptosis inhibitors for the treatment of inflammatory diseases of the gastrointestinal tract. Particularly, the invention relates to inhibitors of the receptor-interacting protein-1 /receptor-interacting protein-3 (RIP1/RIP3) complex, for the treatment of inflammatory diseases or conditions of the gastrointestinal tract, in particular inflammatory bowel disease.